Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interviews

Set Alert for Interviews

Sanofi India Chief, Ex-GSK Exec On Pharma’s Digitization Journey, Tech Confluence

Sanofi India managing director N Rajaram and ex-GSK executive Salil Kallianpur discuss with Scrip a range of aspects around pharma’s digitization efforts including getting the "outside" talent mix right, avoiding digital "intrusion" in physician engagement and the impact of the surge in teleconsultation.

Commercial Digital Health

Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline

Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.

Coronavirus COVID-19 Business Strategies

AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval

Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.

Approvals Immune Disorders

Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals

Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.

Financing Innovation

Takeda To Build On COVID-19 Awareness For Its Dengue Vaccine

Takeda’s vaccines chief Rajeev Venkayya tells Scrip about its COVID-19 vaccines partnerships, and how the pandemic can stimulate action against other infectious disease threats such as Dengue.

Coronavirus COVID-19 Vaccines

TB Alliance CEO On Less Toxic Treatment Regimens, Pretomanid Plans

TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.

Research & Development Clinical Trials

Anocca To Reach Clinical-Stage With T-Cell Therapies After Series B Injection

Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip

Clinical Trials Commercial

Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

Sales & Earnings Business Strategies

Ildong Begins R&D Transformation With 'Quick Win, Fast Fail' Strategy

South Korea’s Ildong Pharmaceutical has begun a major transformation from an OTC-focused firm to an innovative R&D-based operation that aims to compete with global big pharma rivals, helped by both internal and external alliances, its R&D head says in an interview with Scrip.

South Korea Companies

Galapagos Pledges More Restraint On Pipeline Potential

The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."

Clinical Trials Business Strategies

Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid

Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.

Clinical Trials StartUps and SMEs

Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors

Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials. 

Financing Business Strategies
See All
UsernamePublicRestriction

Register